The Rising NAFLD/NASH Epidemic Coupled with High Patient Need Offers Opportunities for Pharmaceutical Manufacturers to Capitalize Across Various Disease Stages, According to Spherix Global Insights
/PRNewswire/ -- The non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH) epidemic is roughly 2.5 times greater than diabetes in the U.S....
Inventiva Pharma Novo Nordisk Spherix Network Madrigal Pharmaceuticals Gastrointestinal Disease Advisory Committee New Spherix
Source: prnewswire.com